Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Convertible Debt (2021 - 2026)

Heron Therapeutics filings provide 7 years of Convertible Debt readings, the most recent being $33.3 million for Q1 2026.

  • On a quarterly basis, Convertible Debt fell 77.75% to $33.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $33.3 million, a 77.75% decrease, with the full-year FY2025 number at $32.7 million, down 78.13% from a year prior.
  • Convertible Debt hit $33.3 million in Q1 2026 for Heron Therapeutics, up from $32.7 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $149.8 million in Q1 2025 to a low of $32.2 million in Q3 2025.
  • Median Convertible Debt over the past 5 years was $149.4 million (2023), compared with a mean of $127.6 million.
  • The widest YoY moves for Convertible Debt: up 0.14% in 2025, down 78.5% in 2025.
  • Heron Therapeutics' Convertible Debt stood at $149.3 million in 2022, then grew by 0.14% to $149.5 million in 2023, then increased by 0.14% to $149.7 million in 2024, then tumbled by 78.13% to $32.7 million in 2025, then increased by 1.8% to $33.3 million in 2026.
  • The last three reported values for Convertible Debt were $33.3 million (Q1 2026), $32.7 million (Q4 2025), and $32.2 million (Q3 2025) per Business Quant data.